The USFDA recently approved tucatinib in combination with trastuzumab for patients with unresectable or metastatic colorectal cancer (RAS wild-type HER2-positive) with disease progression following fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy. Drug details This approval was based on the findings of an open-label, multicenter MOUNTAINEER trial that evaluated the efficacy of this treatment in 84 patients. The details of the study are as follows: A combination of tucatinib and trastuzumab for patients with unresectable or metastatic colorectal cancer showed promising potential to be used as a treatment for patients with these cancers. Do you think the combination of tucatinib and trastuzumab can be effective in treating unresectable or metastatic colorectal cancers?
##References## USFDA Strickler, J. H., Ng, K., Cercek, A., Fountzilas, C., Sanchez, F. A., Hubbard,…
